Please login to the form below

Not currently logged in
Email:
Password:

Takeda regains Prostap from Wyeth

Takeda has signed an agreement with Wyeth to regain the product licence to market Prostap in the UK and Republic of Ireland

Takeda has signed an agreement with Wyeth to regain the product licence to market Prostap in the UK and Republic of Ireland.

Under the agreement, marketing authorisation for Prostap, a prostate cancer therapy, would return to the drug's developer, Takeda. The Japanese-owned company signed over the marketing authorisation for the product in the UK and Republic of Ireland to Wyeth in 1990.

Marketing for the entire Prostap product range in the UK and Republic of Ireland will revert to Takeda from July 1, 2009.

"The addition of Prostap will enrich our product portfolio, which currently consists of Amias, Actos and Competact, and is a logical development of our plan to develop a substantial franchise in the oncology market", commented Trevor Smith, Takeda UK's managing director.

Prostap is used for the treatment of prostate cancer, endometrisis and uterine fibroids. It is marketed in around 80 countries and is considered a gold standard therapy for prostate cancer.

26th March 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...
Emotional Intelligence and Blended Learning in Healthcare
EI and emotional selling are rising up the agenda when it comes to healthcare training. This article outlines how blended learning approaches can help put them into action....

Infographics